Drug Type Antibody drug conjugate (ADC) |
Synonyms ALM 401, ALM401 |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | Preclinical | GB | 30 May 2024 |